SATB1 gene expression and breast cancer prognosis

Lars C. Hanker; Thomas Karn; Loreta Mavrova-Risteska; Eugen Ruckhäberle; Regine Gaetje; Uwe Holtrich; Manfred Kaufmann; Achim Rody; Inka Wiegratz

doi:10.1016/j.breast.2010.10.002

SATB1 gene expression and breast cancer prognosis

Lars C. Hanker^*, Thomas Karn, Loreta Mavrova-Risteska, Eugen Ruckhäberle, Regine Gaetje, Uwe Holtrich, Manfred Kaufmann, Achim Rody, Inka Wiegratz

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Frauenheilkunde und Geburtshilfe

Johann Wolfgang Goethe-Universität

42 Zitate (Scopus)

Abstract

Recently it has been shown that the genome organizer SATB1 plays an important role in breast cancer progression and predicts a poor prognosis. However its prognostic value compared to markers as the estrogen receptor is currently unclear. The expression levels of SATB1 mRNA from Affymetrix microarray in a cohort of 2058 breast cancer samples and its prognostic impact were analyzed. There was no significant difference in disease-free survival among ER negative cancers but instead a benefit for high SATB1 expression among ER positive tumors (p = 0.042). However, even in ER positive cancer no independent prognostic value in multivariate analysis with standard parameters was observed. Thus the use of SATB1 as target or prognostic marker for breast cancer should be viewed with caution and a possible confounding effect of the estrogen receptor status of the tumor should be taken into account when analysing new markers as SATB1.

Originalsprache	Englisch
Zeitschrift	Breast
Jahrgang	20
Ausgabenummer	4
Seiten (von - bis)	309-313
Seitenumfang	5
ISSN	0960-9776
DOIs	https://doi.org/10.1016/j.breast.2010.10.002
Publikationsstatus	Veröffentlicht - 08.2011

Fördermittel

We thank Samira Adel and Katherina Kourtis for expert technical assistance. This work was supported by grants from the Deutsche Krebshilfe, Bonn , the Margarete Bonifer-Stiftung, Bad Soden , the BANSS-Stiftung, Biedenkopf , and the Dr. Robert Pfleger-Stiftung, Bamberg . The funding sources had no roles in the design of the study, analysis and interpretation of the data and writing of the manuscript.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Dokumente

10.1016/j.breast.2010.10.002

Weitere Links

Link to publication in Scopus

Zitieren

@article{7c7268d3ae1d409a97d1cbad6d89053e,

title = "SATB1 gene expression and breast cancer prognosis",

abstract = "Recently it has been shown that the genome organizer SATB1 plays an important role in breast cancer progression and predicts a poor prognosis. However its prognostic value compared to markers as the estrogen receptor is currently unclear. The expression levels of SATB1 mRNA from Affymetrix microarray in a cohort of 2058 breast cancer samples and its prognostic impact were analyzed. There was no significant difference in disease-free survival among ER negative cancers but instead a benefit for high SATB1 expression among ER positive tumors (p = 0.042). However, even in ER positive cancer no independent prognostic value in multivariate analysis with standard parameters was observed. Thus the use of SATB1 as target or prognostic marker for breast cancer should be viewed with caution and a possible confounding effect of the estrogen receptor status of the tumor should be taken into account when analysing new markers as SATB1.",

author = "Hanker, \{Lars C.\} and Thomas Karn and Loreta Mavrova-Risteska and Eugen Ruckh{\"a}berle and Regine Gaetje and Uwe Holtrich and Manfred Kaufmann and Achim Rody and Inka Wiegratz",

note = "Funding Information: We thank Samira Adel and Katherina Kourtis for expert technical assistance. This work was supported by grants from the Deutsche Krebshilfe, Bonn , the Margarete Bonifer-Stiftung, Bad Soden , the BANSS-Stiftung, Biedenkopf , and the Dr. Robert Pfleger-Stiftung, Bamberg . The funding sources had no roles in the design of the study, analysis and interpretation of the data and writing of the manuscript.",

year = "2011",

month = aug,

doi = "10.1016/j.breast.2010.10.002",

language = "English",

volume = "20",

pages = "309--313",

journal = "Breast",

issn = "0960-9776",

publisher = "S. Karger AG",

number = "4",

}

TY - JOUR

T1 - SATB1 gene expression and breast cancer prognosis

AU - Hanker, Lars C.

AU - Karn, Thomas

AU - Mavrova-Risteska, Loreta

AU - Ruckhäberle, Eugen

AU - Gaetje, Regine

AU - Holtrich, Uwe

AU - Kaufmann, Manfred

AU - Rody, Achim

AU - Wiegratz, Inka

N1 - Funding Information: We thank Samira Adel and Katherina Kourtis for expert technical assistance. This work was supported by grants from the Deutsche Krebshilfe, Bonn , the Margarete Bonifer-Stiftung, Bad Soden , the BANSS-Stiftung, Biedenkopf , and the Dr. Robert Pfleger-Stiftung, Bamberg . The funding sources had no roles in the design of the study, analysis and interpretation of the data and writing of the manuscript.

PY - 2011/8

Y1 - 2011/8

N2 - Recently it has been shown that the genome organizer SATB1 plays an important role in breast cancer progression and predicts a poor prognosis. However its prognostic value compared to markers as the estrogen receptor is currently unclear. The expression levels of SATB1 mRNA from Affymetrix microarray in a cohort of 2058 breast cancer samples and its prognostic impact were analyzed. There was no significant difference in disease-free survival among ER negative cancers but instead a benefit for high SATB1 expression among ER positive tumors (p = 0.042). However, even in ER positive cancer no independent prognostic value in multivariate analysis with standard parameters was observed. Thus the use of SATB1 as target or prognostic marker for breast cancer should be viewed with caution and a possible confounding effect of the estrogen receptor status of the tumor should be taken into account when analysing new markers as SATB1.

AB - Recently it has been shown that the genome organizer SATB1 plays an important role in breast cancer progression and predicts a poor prognosis. However its prognostic value compared to markers as the estrogen receptor is currently unclear. The expression levels of SATB1 mRNA from Affymetrix microarray in a cohort of 2058 breast cancer samples and its prognostic impact were analyzed. There was no significant difference in disease-free survival among ER negative cancers but instead a benefit for high SATB1 expression among ER positive tumors (p = 0.042). However, even in ER positive cancer no independent prognostic value in multivariate analysis with standard parameters was observed. Thus the use of SATB1 as target or prognostic marker for breast cancer should be viewed with caution and a possible confounding effect of the estrogen receptor status of the tumor should be taken into account when analysing new markers as SATB1.

UR - https://www.scopus.com/pages/publications/79960570808

U2 - 10.1016/j.breast.2010.10.002

DO - 10.1016/j.breast.2010.10.002

M3 - Journal articles

C2 - 20980149

AN - SCOPUS:79960570808

SN - 0960-9776

VL - 20

SP - 309

EP - 313

JO - Breast

JF - Breast

IS - 4

ER -

SATB1 gene expression and breast cancer prognosis

Abstract

Fördermittel

UN SDGs

Dokumente

Weitere Links

Fingerprint

Zitieren